Market Access Views & Analysis

Views & Analysis

Market Access

Beyond Market Access: Why healthcare-system understanding is...

Healthcare-system literacy, and the ability to contribute to system shaping, must become part of how healthcare leaders make decisions.

Market Access

Chinese flag atop pills on black background

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Market Access

Two business hands outstretched, one weighing cash, the other drugs, for balance

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Market Access

$100 notes in pill bottle on aquamarine background with spilled pills

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access

From first approval to lasting value: What sets successful e...

Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.

Market Access

drug pricing in the UK, pills overlain on map

Request to look further into NICE non-submissions in the fut...

Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.

Beyond Market Access: Why healthcare-system understanding is...

Is the next generation of Chinese biotech ready to go global...

What the revised 340B rebate pilot programme means for pharm...

How new PBM transparency rules will alter drug pricing

From first approval to lasting value: What sets successful e...

Request to look further into NICE non-submissions in the fut...

ViiV's Cabenuva enhances control of unsuppressed HIV

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks